Head-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers
Anika Therapeutics (NASDAQ: ANIK) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Anika Therapeutics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation.
This table compares Anika Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anika Therapeutics Competitors||-13,072.91%||230.07%||-22.93%|
Valuation and Earnings
This table compares Anika Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Anika Therapeutics||$111.36 million||$56.02 million||24.72|
|Anika Therapeutics Competitors||$578.59 million||$241.91 million||-6.43|
Anika Therapeutics’ competitors have higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
84.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 6.6% of Anika Therapeutics shares are held by company insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for Anika Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anika Therapeutics Competitors||190||909||1681||67||2.57|
As a group, “Biopharmaceuticals” companies have a potential upside of 2.37%. Given Anika Therapeutics’ competitors higher possible upside, analysts plainly believe Anika Therapeutics has less favorable growth aspects than its competitors.
Risk & Volatility
Anika Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Anika Therapeutics’ competitors have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.